Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

NCT02221414 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Linagliptin/Metformin FDC
DRUG: Linagliptin
DRUG: Metformin

Sponsor

Boehringer Ingelheim